URSODIOL FOR PRIMARY BILIARY CIRRHOSIS - AASLD

More documents

Recommendations

Info

WORSE PROGNOSIS IF: • ANA + (Yang W, et al Clin Gastroenterol Hepatol 2004;2:1116-22) • Anti-centromere + (Yang W, et al Clin Gastroenterol Hepatol 2004;2:1116-22) • Gp210 + (Nakamura M, et al. J Hepatol 2005;42:386-92)
OVERLAP FEATURES • IgG > 2.0 mg/dL • ANA/SMA > 1:80 • Interface hepatitis • Presence of other autoimmune diseases
Page 1 and 2: Keith D. Lindor, MD Cholestatic Dis
Page 3 and 4: UPDATE • PBC • PSC • Complica
Page 5 and 6: EPIDEMIOLOGY OF PBC Changes Over Ti
Page 7: PROGNOSTIC MODELS IN PBC Dickson et
Page 11: PRIMARY BILIARY CIRRHOSIS • DIAGN
Page 14: DIAGNOSIS OF AMA PBC • Compatible
Page 18 and 19: PREDICTED SURVIVAL RATES Corpechot
Page 20 and 21: SURVIVAL TO DEATH OR LIVER TRANSPLA
Page 22 and 23: COMBINATION THERAPY FOR PBC • Urs
Page 24 and 25: THERAPY FOR PBC - CURRENT RECOMMEND
Page 26 and 27: PRIMARY SCLEROSING CHOLANGITIS •
Page 28: PRIMARY SCLEROSING CHOLANGITIS •
Page 32 and 33: PRIMARY SCLEROSING CHOLANGITIS •
Page 34 and 35: SURVIVAL IN PSC - SMALL DUCT VS. LA
Page 36 and 37: PSC SURVIVAL IN OLMSTED COUNTY MINN
Page 38 and 39: PRIMARY SCLEROSING CHOLANGITIS Mana
Page 40 and 41: AUTOIMMUNE PANCREATITIS/ CHOLANGITI
Page 42 and 43: HIGH DOSE URSO IN PSC Primary Endpo
Page 44 and 45: Incidence of Cholangiocarcinoma Cum
Page 46 and 47: LIVER TRANSPLANTATION Cholestatic L

URSODIOL FOR PRIMARY BILIARY CIRRHOSIS - AASLD

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?